ArticleFrontiers in oncology2026
Prognostic evaluation using nutrition-inflammation biomarkers from routine blood tests in metastatic breast cancer: a Boruta algorithm-optimized feature selection study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate and compare the prognostic value of multiple nutrition- and inflammation-related indices derived from routine blood tests in patients with metastatic breast cancer, and to identify the most clinically applicable indicators. Methods: This retrospective study analyzed data from 163 newly diagnosed breast cancer patients with a single distant metastasis. Seventeen nutrition- and inflammation-related indices were assessed, including ALI, NLR, dNLR, SII, SIRI, PLR, MLR, NMLR, PNI, GLR, AGR, GNRI, mGNRI, TP, PA, TRF, and ALB. Kaplan-Meier survival analysis and Cox regression models were used to evaluate the associations between these indices and overall survival (OS). The predictive performance of each index was assessed using the concordance index (C-index), and the Boruta algorithm was applied to identify key variables. Restricted cubic spline (RCS) regression was performed to explore potential nonlinear relationships between indices and OS, and subgroup analyses were conducted to examine index performance across different clinical characteristics. Results: Multivariate Cox regression analysis identified MLR, SIRI, ALI, AGR, and PA as independent predictors of OS in patients with metastatic breast cancer. Patients with MLR ≥ 0.33 had a 3.94-fold increased risk of death, and those with SIRI ≥ 1.70 had a 3.32-fold increased risk. In contrast, patients with ALI ≥ 53.99, AGR ≥ 1.11, and PA ≥ 181 had 73%, 76%, and 77% reductions in mortality risk, respectively. Inflammation-related indices demonstrated stronger predictive value for short-term (1-year) outcomes, whereas nutrition-related indices were more effective in predicting medium- to long-term (3-5 years) survival. ALI and MLR showed consistent prognostic performance across all clinical subgroups, while SIRI, AGR, and PA exhibited significant interactions in specific subgroups. Conclusion: Nutrition- and inflammation-related indices derived from routine blood tests-particularly MLR, SIRI, ALI, AGR, and PA-serve as effective tools for prognostic assessment in metastatic breast cancer. Among these, ALI and MLR have universal applicability across patient subgroups, offering clinicians valuable guidance for optimizing patient management strategies and improving survival and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.